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a b s t r a C t
background: recently, the dutch association of 
Gastroenterology and Hepatology issued new guidelines 
for the treatment of chronic hepatitis C virus (HCV). these 
guidelines reflect the current standard of care. before these 
guidelines were published and implemented we (1) studied 
the current clinical care of HCV patients among dutch 
physicians, and (2) identified areas for future refinement 
in the current treatment. 
methods: We conducted a non-targeted survey among 
dutch medical specialists in Gastroenterology, Hepatology 
and internal medicine who actively treat HCV patients. the 
questionnaire contained items about facility, duration and 
dosing of treatment, and side effect management using 
clinical vignettes followed by short questions. 
results: We received 49 questionnaires from treating 
HCV specialists. the majority (65%) of respondents treat 
HCV patients during regular outpatient clinics, while 
35% treat these patients in a separate setting dedicated 
to the care of HCV patients. the majority of physicians 
follow the stipulated dosage regimens of pegylated 
interferon (88%) and ribavirin (83%). a minority (13%) 
exceed the advised dosage of ribavirin. side effects such 
as neutropenia are mostly managed by decreasing the 
interferon dosage (42%). some 35% of physicians reduce 
ribavirin if haemoglobin levels drop below 5.4 mmol/l, and 
41% initiate erythropoietin treatment.
Conclusion: dutch clinical practice reflects the recently 
issued HCV guidelines. an important area of refinement 
in treatment of HCV is the management of side effects.
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i n t r o d U C t i o n
Chronic hepatitis C virus (HCV) is one of the most 
common chronic viral infections throughout the world 
and is a primary cause of cirrhosis and hepatocellulair 
carcinoma.1 Treatment of HCV has improved steadily 
during the last decade, and with the current standard 
of care, that is treatment with pegylated interferon and 
ribavirin, sustained virological response (SVR) rates of 50% 
among genotypes 1 and 4, and 80% among genotypes 2 
and 3 have become possible.2,3 
The selection of patients who benefit most from therapy 
and close monitoring of hepatitis C treatment are crucial 
components of hepatitis C therapy. These aspects, and the 
wealth of clinical data that stem from a large number of 
clinical trials, have led to the formulation of international 
guidelines.4,5 Given the intensive treatment schedule with side 
effects, long treatment duration and high costs of therapy, it 
is important that physicians follow evidence-based guidelines 
in order to improve patient outcome and give the best care 
available.4,5 Recently, the first Dutch national guideline 
‘Treatment of chronic hepatitis C virus infection’ was 
formulated by the Dutch Association of Gastroenterologists 
and Hepatologists.6 This guideline for HCV mono-infection 
provides recommendations on diagnostic evaluation, choice of 
the (initial) antiviral treatment and the follow-up during and 
after antiviral therapy (table 1, figure 1).6 
Although clinical trials have demonstrated the benefit of 
combination therapy in patients with chronic HCV, how 
this translates into actual benefit in practice that can be 
attributed to knowledge of and adherence to guidelines is 
unclear. The primary objective of this study was to evaluate 
current clinical practice among Dutch physicians who 
actively see and treat chronic HCV patients. A secondary 
objective was to identify dimensions of the guideline that 
potentially benefit from refinement or adjustment. 
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m e t H o d s 
We conducted a non-targeted survey among Dutch medical 
specialists in Gastroenterology, Hepatology and Internal 
Medicine. These physicians were selected from membership 
directories of the Dutch Society of Hepatology and the 
Infectious Disease Society of the Netherlands and were sent 
a postal questionnaire; physicians who actively treated HCV 
patients were asked to return the questionnaire. 
The postal questionnaire included four important issues: 
the first part discussed the setting of the treatment: a 
regular outpatient clinic or a separate setting dedicated to 
the care of HCV patients. The second and third part of the 
survey focused on peginterferon and ribavirin treatment 
for HCV patients: detailed questions using clinical 
vignettes were included about the treatment duration and 
dosage of the drugs, respectively. The last part focused on 
side effects, their consequences, and management in terms 
of dose reduction or treatment of possible side effects. 
The questionnaire consisted of clinical vignettes followed 
by a mix of short multiple-choice and open-ended 
questions. For example: ‘A male HCV genotype 1 patient 
starts the combination therapy (peginterferon 180 µg/
week and weight-based ribavirin daily); at the start of the 
treatment the haemoglobin (Hb) level is 8.0 mmol/l. After 
eight weeks the patient’s Hb has decreased to 5.4 mmol/l. 
What to do? 1) Continue combination therapy. 2) Stop 
ribavirin (whether or not temporarily). 3) Reduce ribavirin 
to 50%. 4) Give erythropoietin. 5) Give blood transfusion.’
Data from returned questionnaires were entered into a 
Microsoft Access database, and frequency tables were 
provided by SPSS 14.0 for Windows. 
table 1. Main recommendations for treatment and management of chronic HCV patients6
dutch guideline6 % followed 
guideline*
dosage
HCV genotype 1 and 4 Peg-IFN α-2a 180 µg/week + weight-based RBV/day or 83%
Peg-IFN α-2b 1.5 µg/kg/week + weight-based RBV/day
HCV genotype 2 and 3 Peg-IFN α-2a 180 µg/week + 800 mg RBV/day or 88%
Peg-IFN α-2b 1.5 µg/kg/week + weight-based RBV/day
duration
HCV genotype 1 and 4 48 weeks of treatment 67%
Exception: <600,000 viral load (IU/ml) at baseline with RVR: 24 weeks of treatment 55%
HCV genotype 2 and 3 24 weeks of treatment 70%
Exception: with RVR: 12-16 weeks of treatment -
side effects
Neutropenia ANC <0.75 x 109/l: PEG-IFN dose to 75% 35%
ANC <0.375 x 109/l: PEG-IFN dose to 50% -
Anaemia Hb <5.0 mmol/l: give erythropoietin 25%
Hb <4.0 mmol/l: decrease dose RBV to 800 mg/day and give erythropoietin and blood transfusion -
HCV = hepatitis C virus; Peg-ifn = peginterferon; rbV = ribavirin; rVr = rapid viral response; anC = absolute neutrophil count;  
Hb = haemoglobin. *% physicians who treat according to the dutch guideline.
r e s U l t s
A total of 64 questionnaires were received. Although explicitly 
indicated, 15 responding specialists were not actively treating 
HCV patients and were excluded from further analysis. 
Forty-nine questionnaires were suitable for analysis. 
setting
The majority (65%) of respondents treat HCV patients 
during regular outpatient clinics, while 35% treat patients 
in a separate setting dedicated to the care of HCV patients.
Viral load, genotype and length of treatment
Week 12 and 24 measurements of viral load are important 
to judge treatment outcome. When asked, 67% of 
physicians would treat HCV genotype 1 patients with a 
detectable HCV viral load at week 12 and an undetectable 
HCV viral load at 24 weeks for a total of 48 weeks (table 
1), while 13 of the 49 respondents (27%) choose longer 
treatment (72 weeks). This is an area of controversy since 
the guideline indicates 48 weeks, but recent evidence 
suggests that prolonged treatment up to 72 weeks is 
beneficial in these cases.7,8
The guideline recommends treating HCV genotype 3 
patients for 24 weeks. Some 70% of respondents treat 
HCV genotype 3 patients with significant cirrhosis for 
24 weeks, while a minority (22%) will treat for 48 weeks. 
For HCV genotype 3 patients who had a negative viral 
load at week 4, the guideline recommends treating for 
12 to 16 weeks. Thirty-seven percent of the respondents 
would treat for this period. The remainder choose a longer 
treatment duration than currently advised in the guideline. 
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figure 1. Flowchart for the treatment of patients with chronic hepatitis C mono-infection according to the recently 
issued Dutch guideline6
A) HCV genotype 1
Week 4
Week 12
HCV RNA negative RVR: if baseline HCV RNA <6000,000 IU/ml, 
therapy can be stopped after 24 weeks
HCV RNA positive Determine HCV RNA at week 12
HCV RNA negative EVR: 48 weeks treatment
HCV RNA <2 log
10
 IU/ml 
(c/ml) decline
No EVR: stop
HCV RNA ≥2 log
10
 IU/ml 
(c/ml) decline and HCV RNA 
≥50 log10 IU/ml
EVR: determine HCV RNA 
at week 24
Week 24
HCV RNA positive Stop
HCV RNA negative Continue treatment 
untill week 48
B) HCV genotype 4
Week 4
Week 12
HCV RNA negative RVR: stop treatment after 24 weeks
HCV RNA positive Determine HCV RNA at week 12
HCV RNA negative EVR: 48 weeks treatment
HCV RNA <2 log
10
 IU/ml 
(c/ml) decline
No EVR: Stop
C) HCV genotype 2 and 3
Week 4
HCV RNA negative reatment can be stopped at week 12-16
HCV RNA positive 24 weeks treatment
HCV RNA ≥2 log
10
 IU/ml 
(c/ml) decline and HCV RNA 
≥50 log
10
 IU/ml
EVR: determine HCV RNA 
at week 24
Week 24
HCV RNA positive Stop
HCV RNA negative Continue treatment 
untill week 48
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Respondents were also divided on treatment duration of 
genotype 1 patients with low viraemia (<600,000 IU/ml) 
at the start of treatment, and a negative viral load at week 
4. While following the guideline, some 55% would treat for 
24 weeks, and 45% would treat for 48 weeks.
ribavirin
The recommended dosage of ribavirin for HCV genotype 1 
patients is weight-based. Indeed, the majority of physicians 
treat an HCV genotype 1 patient with a weight of 104 
kg with ribavirin on a weight-based schedule (83%). A 
minority (13%) consistently exceeds this dosage. 
Peginterferon 
The vignette on the peginterferon dosage in an HCV genotype 
1 patient weighing 150 kg shows that 88% of the physicians 
administer the dosage exactly as stated in the guideline. Thus, 
peginterferon-α-2a, 180 µg/week, or weight-based peginter-
feron-alfa-2b, 1.5 µg/week. The remainder choose a higher 
dosage than currently advised in the guideline.
side effect management
Neutropenia is a common event in HCV combination 
therapy and is usually attributed to the peginterferon 
component. Upon managing a patient with profound 
neutropenia (0.8 x 109/l), 35% would continue current 
treatment, 42% would reduce (halve) the prescribed dosage 
of peginterferon, and 15% stop peginterferon (figure 2).
Anaemia is caused by ribavirin-induced haemolysis, and 
if asked to decide for a patient with haemoglobin <5.4 
mmol, the majority of physicians (41%) would initiate 
erythropoietin treatment, while 35% of physicians would 
reduce the ribavirin. Twenty-five percent continue both 
pegylated interferon and ribavirin unchanged (figure 3). 
figure 2. Management choices in treatment of 
neutropenia 0.8 x 109/l
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figure 3. Management choices in treatment of 
haemoglobin levels below 5.4 mmol/l
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d i s C U s s i o n
Our survey shows that most physicians treat patients with 
HCV in clinical practice according to this recently issued 
HCV guideline. 
Still there are some areas of controversy. Almost half of 
the physicians treat HCV genotype 1 and 3 patients with 
RVR longer than currently needed. In terms of financial 
aspects, occurrence of severe side effects and convenience 
for patients, shorter treatment duration with retained 
efficacy is desirable. 
Some 13% of the physicians use higher ribavirin dosages 
than currently advised. Some studies show that a higher 
starting dose of ribavirin is associated with a lower relapse 
rate and higher rate of SVR.9-11 High-dose ribavirin is also 
associated with more frequent and serious side effects such 
as anaemia, which require erythropoietin in many cases.9-11 
More studies are necessary to judge whether the benefits of 
a higher ribavirin dosage needed to achieve SVR outweigh 
the disadvantages of the side effects.12
Management of side effects has low evidential value 
and the current literature is mostly based on expert 
opinion. When a side effect, e.g. neutropenia or anaemia, 
occurs peginterferon and ribavirin are often reduced or 
stopped too soon,13 and this may hamper the achievement 
of SVR. On the other hand, if treatment of anaemia 
by erythropoietin is initiated too early, it leads to 
unnecessary expenses.9,14 Supporting evidence in order 
to issue guidelines is clearly needed. Along the same 
line, neutropenia due to peginterferon can be controlled 
by granulocyte colony stimulating factor, but it is unclear 
which cut-off point should be used for initiating therapy.
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This study has some limitations. We did not ask for 
respondents’ demographics, professional background 
and/or hospital setting. It is unclear whether our findings 
are generalisable to all Dutch medical specialists in 
Gastroenterology, Hepatology and Internal Medicine. 
Altogether, data from our survey indicate that Dutch 
physicians treat their HCV patients as described in the 
recently issued HCV treatment guideline. There is a 
paucity of data that enables evidence-based management 
of side effects during HCV therapy. 
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